Literature DB >> 20552547

P-cadherin, vimentin and CK14 for identification of basal-like phenotype in breast carcinomas: an immunohistochemical study.

Bárbara Sousa1, Joana Paredes, Fernanda Milanezi, Nair Lopes, Diana Martins, Rozany Dufloth, Daniella Vieira, André Albergaria, Luiz Veronese, Vitor Carneiro, Sílvia Carvalho, José Luis Costa, Luiz Zeferino, Fernando Schmitt.   

Abstract

INTRODUCTION: The most suitable immunohistochemical criterion to identify basal-like breast carcinomas (BLBC), a molecular subgroup of breast cancer associated with poor prognosis, is the triple negative phenotype along with CK5 and/or EGFR immunoreactivity. However, several putative basal markers have been suggested as alternatives to identify BLBC with more accuracy. EXPERIMENTAL
DESIGN: The expression of CK5, EGFR, P-cadherin, CK14, Vimentin and p63 were evaluated in 462 invasive breast carcinomas to determine their sensitivity and specificity for BLBC identification.
RESULTS: P-cadherin and CK5 showed higher sensitivity values, while EGFR, Vimentin and CK14 were the most specific markers. The combination of CK5 with P-cadherin, Vimentin or CK14 proved to be a reliable option for distinguishing the basal phenotype, compared to the "gold standard" pair CK5/EGFR. Furthermore, P-cadherin was still able to recognize a large number of putative BLBC among the "unclassified" group (ER-/PR-/HER2-/CK5-/EGFR-).
CONCLUSIONS: P-cadherin, Vimentin and CK14 can recognize BLBC already identified in triple negative/ CK5 and/or EGFR+ tumors, and due to P-cadherin sensitivity for BLBC identification this marker can reliably recruit a large number of breast carcinomas with basal phenotype among immunohistochemistry triple negative/ CK5 and/or EGFR - pool of tumors. Although they need GEP validation, our results can introduce the idea of these markers as additional options in the daily workup of breast pathology laboratories to identify BLBC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20552547     DOI: 10.14670/HH-25.963

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  22 in total

1.  The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.

Authors:  Jennifer L Dine; Ciara C O'Sullivan; Donna Voeller; Yoshimi E Greer; Kathryn J Chavez; Catherine M Conway; Sarah Sinclair; Brandon Stone; Laleh Amiri-Kordestani; Anand S Merchant; Stephen M Hewitt; Seth M Steinberg; Sandra M Swain; Stanley Lipkowitz
Journal:  Breast Cancer Res Treat       Date:  2016-01-12       Impact factor: 4.872

2.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers.

Authors:  Sofia Levva; Vassiliki Kotoula; Ioannis Kostopoulos; Kyriaki Manousou; Christos Papadimitriou; Kyriaki Papadopoulou; Sotiris Lakis; Kyriakos Koukoulias; Vasilios Karavasilis; George Pentheroudakis; Eufemia Balassi; Flora Zagouri; Ioannis G Kaklamanos; Dimitrios Pectasides; Evangelia Razis; Gerasimos Aravantinos; Pavlos Papakostas; Dimitrios Bafaloukos; Grigorios Rallis; Helen Gogas; George Fountzilas
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

4.  Vimentin DNA methylation predicts survival in breast cancer.

Authors:  Jacob Ulirsch; Cheng Fan; George Knafl; Ming Jing Wu; Brett Coleman; Charles M Perou; Theresa Swift-Scanlan
Journal:  Breast Cancer Res Treat       Date:  2012-12-13       Impact factor: 4.872

5.  Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors.

Authors:  Steven T Sizemore; Gina M Sizemore; Christine N Booth; Cheryl L Thompson; Paula Silverman; Gurkan Bebek; Fadi W Abdul-Karim; Stefanie Avril; Ruth A Keri
Journal:  Breast Cancer Res Treat       Date:  2014-05-22       Impact factor: 4.872

6.  Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.

Authors:  Seema Sethi; Fazlul H Sarkar; Quratulain Ahmed; Sudeshna Bandyopadhyay; Zeina A Nahleh; Assaad Semaan; Wael Sakr; Adnan Munkarah; Rouba Ali-Fehmi
Journal:  Transl Oncol       Date:  2011-08-01       Impact factor: 4.243

7.  P-cadherin expression and basal-like subtype in breast cancers.

Authors:  N Liu; Q Yu; T J Liu; Estifanos P Gebreamlak; S L Wang; R J Zhang; J Zhang; Y Niu
Journal:  Med Oncol       Date:  2012-04-01       Impact factor: 3.064

8.  Cadherin cell adhesion system in canine mammary cancer: a review.

Authors:  Adelina Gama; Fernando Schmitt
Journal:  Vet Med Int       Date:  2012-08-22

9.  Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?

Authors:  André Albergaria; Sara Ricardo; Fernanda Milanezi; Vítor Carneiro; Isabel Amendoeira; Daniella Vieira; Jorge Cameselle-Teijeiro; Fernando Schmitt
Journal:  BMC Cancer       Date:  2011-07-15       Impact factor: 4.430

10.  CCAAT/enhancer binding protein β (C/EBPβ) isoforms as transcriptional regulators of the pro-invasive CDH3/P-cadherin gene in human breast cancer cells.

Authors:  André Albergaria; Carlos Resende; Ana Rita Nobre; Ana Sofia Ribeiro; Bárbara Sousa; José Carlos Machado; Raquel Seruca; Joana Paredes; Fernando Schmitt
Journal:  PLoS One       Date:  2013-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.